VivoSeq
Oncology

Cancer of Unknown Primary

0

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Cancer of Unknown Primary is an early-stage landscape with 0 programs across 2 companies. The most active players are Eastern Cooperative Oncology Group, Valerio Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

0 programs

PreclinicalV

Valerio Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Unknown status2 · 17%
Terminated1 · 8%
Withdrawn1 · 8%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary
Not yet recruiting·ZZhiguo Luo, MD, PhD·Phase 2·NCT06869174·50 enrolled
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00066781·31 enrolled
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00357630·52 enrolled
Trial of Pembrolizumab in Cancer of Unknown Primary
Completed·IImperial College London·Phase 2·NCT03752333·35 enrolled
Sintilimab in Cancer of Unknown Primary
Completed·MM.D. Anderson Cancer Center·Phase 2·NCT05024968·10 enrolled
Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary
Completed·Alliance for Clinical Trials in Oncology·Phase 2·NCT00936702·46 enrolled
Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary
Completed·VValerio Therapeutics·Phase 2·NCT00873119·89 enrolled
A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)
Completed·FFondazione del Piemonte per l'Oncologia·Phase 2·NCT02607202·57 enrolled
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Terminated·—·Phase 2·NCT00003526·8 enrolled
Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin
Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00119314
Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin
Unknown status·—·Phase 3·NCT00003558·140 enrolled
FAPI-CUP- Evaluating FAPI as a Novel Radiopharmaceutical for Cancer of Unknown Primary
Unknown status·PPeter MacCallum Cancer Centre, Australia·N/A·NCT05263700·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)